Monash IVF GroupASX:MVF 78 EBITDA Margin % is 18.57% as of Dec. 2025, which is 21% below its 10-year median of 23.54. GuruFocus rates ASX:MVF with a GF Score™ of 78/100 and a GF Value™ of A$1.39 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Monash IVF Group ranks better than 71.08% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Monash IVF Group's EBITDA for the
six
months ended in Dec. 2025 was A$25.6 Mil. Monash IVF Group's Revenue for the
six
months ended in Dec. 2025 was A$137.9 Mil. Therefore, Monash IVF Group's EBITDA margin for the quarter that ended in Dec. 2025 was 18.57%.
Monash IVF Group (ASX:MVF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Monash IVF Group EBITDA Margin % Related Terms
Monash IVF Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Monash IVF Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:MVF vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Monash IVF Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monash IVF Group EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Monash IVF Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Monash IVF Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monash IVF Group (ASX:MVF) has a EBITDA Margin % of 18.57% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Monash IVF Group and its competitors. This is 21% below median its historical median of 23.54. Over the past decade, Monash IVF Group's EBITDA Margin % has ranged from 4.23 to 31.69. According to the industry distribution chart, Monash IVF Group ranks #59 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 28.9%.
Is Monash IVF Group's EBITDA Margin % too high?
Monash IVF Group's current EBITDA Margin % of 18.57% is 21% below median its 10-year median of 23.54. Over the past 10 years, this metric has ranged from a low of 4.23 to a high of 31.69. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. Monash IVF Group's value of 18.57% is 257.1% above this industry median. Based on the distribution chart, Monash IVF Group ranks #59 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Monash IVF Group has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Monash IVF Group's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Monash IVF Group ranks #59 out of 204 companies for EBITDA Margin %. This puts Monash IVF Group in the upper half of its industry. The industry median EBITDA Margin % is 5.20. Monash IVF Group's value of 18.57% is 257.1% above this benchmark. Historically, Monash IVF Group's own EBITDA Margin % has ranged from 4.23 to 31.69 over the past decade. While the company's 10-year median is 23.54 vs. the industry median of 5.20, Monash IVF Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Monash IVF Group's current EBITDA Margin % of 18.57% is 257.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Monash IVF Group and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monash IVF Group's current EBITDA Margin % is 18.57%, which is 21% below median its own 10-year median of 23.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monash IVF Group stock overvalued right now?
Based on GuruFocus' analysis, Monash IVF Group (ASX:MVF) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.39, compared to a current price of A$0.71 — trading 48.9% below its estimated fair value. The current EBITDA Margin % is 18.57%, which is 21% below median its 10-year median of 23.54 and 257.1% above the Medical Diagnostics & Research industry median of 5.20. Monash IVF Group's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Monash IVF Group (ASX:MVF), the current EBITDA Margin % is 18.57% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Monash IVF Group (ASX:MVF) Overvalued in 2026?
Based on GuruFocus' analysis, Monash IVF Group stock appears to be undervalued.
The current stock price of A$0.71 is trading 48.9% below its estimated GF Value™ of A$1.39.
GuruFocus considers Monash IVF Group to be Possible Value Trap.
Key valuation signals for ASX:MVF:
EBITDA Margin %: 18.57% (21% below median its 10-year median of 23.54)
GF Value™: A$1.39 vs. price of A$0.71 (48.9% below fair value)
Industry Position: 257.1% above the Medical Diagnostics & Research median (#59 of 204)
No single metric tells the full story. See the ASX:MVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Monash IVF Group Ltd is a provider of fertility services, specializing in Assisted Reproductive Services (ARS) and genetic care across Australia and South East Asia. The Group operates two main segments: Australia IVF and Ultrasound, which offer ARS, ultrasound, and related women's health services, and International IVF, which provides assisted reproductive care in South East Asia. The majority of revenue is generated from the Australian segment through its brands such as Fertility Solutions, KL Fertility, Monash IVF, Repromed, and others.
78GF Score
Get the complete analysis for ASX:MVF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MVF has been successfully added to your 
